Dianthus price target raised to $65 from $52 at Stifel

Stifel analyst Alex Thompson raised the firm’s price target on Dianthus (DNTH) to $65 from $52 and keeps a Buy rating on the shares following the positive Phase 2 MaGic trial in AChR+ Myasthenia Gravis. Following the data, the firm’s model now reflects higher MG odds of success of 75%, up from a prior 50% forecast, the analyst noted.